Which drug is FDA-indicated for chronic tophaceous and/or refractory gout?

• A. Pegloticase
• B. Allopurinol
• C. Febuxostat
• D. Colchicine

Answer: (A)

Pegloticase is used for chronic tophaceous and/or refractory gout because it works differently from standard urate-lowering drugs. It’s a PEGylated recombinant uricase that directly metabolizes uric acid into allantoin, a more soluble form that the body easily excretes. This makes it effective in patients whose gout remains active or tophi persist despite conventional therapy with options like allopurinol or febuxostat. Therefore, it’s FDA-indicated specifically for adults with chronic refractory gout or tophaceous disease.

In contrast, allopurinol and febuxostat lower uric acid by inhibiting its production (xanthine oxidase inhibitors) and are typically first-line for many patients, not limited to refractory cases. Colchicine is mainly used to treat acute gout flares or as chronic prophylaxis, not as a urate-lowering agent for chronic tophaceous disease.